Randomized Sitagliptin Withdrawal Study (MK-0431-845)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 746 participants.

Also called NCT02738879

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 746 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02738879
  • EudraCT 2015-004990-34
Other papers using this trial's data
  • Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study Diabetes, obesity & metabolism, 2019-04 DOI, PubMed 30393950, PMC6587501 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02738879. Randomized; double masking; primary purpose treatment. Start 2016-05-09 (actual); primary completion 2018-01-22 (actual). Results posted on 2019-02-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo to sitagliptin
Intervention (Drug)
Metformin
Intervention (Drug)
Metformin XR
Intervention (Drug)
Insulin glargine
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02738879
Content hash
78446d12d697ec1309bc4161ccf741354355f787d539ed2542cfcfd0029446eb